GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)

Phase 3

GSK plc (GSK)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Infections, Meningococcal

View Full Landscape

Drug Information

Target Indication

Infections, Meningococcal

Clinical Trial

NCT00614614

Last updated: 2/10/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA4/20/2012

Nimenrix

Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal diseases caused by Neisseria meningitidis group A, C, W-135, and Y.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

GSK

GSK plc

Pharmaceutical Preparations•Europe•NYSE

Related Pipeline

FluoridePhase 3

Dental Caries

Combined Hepatitis A and B vaccinePhase 3

Hepatitis B

62.5/25mcgPhase 3

Pulmonary Disease, Chronic Obstructive

Losmapimod 7.5 mg twice dailyPhase 3

Acute Coronary Syndrome

Haemophilus influenzae type b- and meningococcal (vaccine)Phase 3

Haemophilus Influenzae Type b

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts